You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
羚鋭製藥(600285.SH):擬收購銀谷製藥100%股權
格隆匯 12-04 17:22

格隆匯12月4日丨羚鋭製藥(600285.SH)公佈,公司擬使用自有資金收購銀谷製藥有限責任公司(簡稱“銀谷製藥”、“標的公司”)100%的股權。公司與銀谷控股集團有限公司、王文軍先生簽訂《收購意向書》,各方就股權收購事宜達成初步合作意向,公司擬使用自有資金購買標的公司100%股權,根據公司當前對標的公司業務、財務及團隊等情況的初步評估,其綜合估值暫定為不超過人民幣78,212萬元(最終以第三方專業機構出具的評估報吿、審計報吿中載明的評估值為基礎,由公司與交易各方協商確定)。銀谷製藥其他股東已向銀谷集團授權,同意銀谷集團代表其對外洽談股權轉讓事宜。

谷製藥自主完成我國首個高選擇性抗膽鹼能受體拮抗劑1類新藥研發上市,即苯環喹溴銨鼻噴霧劑(商品名:必立汀),同時擁有國內首仿藥品鮭降鈣素注射液(商品名:固泰寧)、鮭降鈣素鼻噴霧劑(商品名:金爾力);另有吸入用鹽酸氨溴索溶液(商品名:力希暢)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account